AUCKLAND, New Zealand--(BUSINESS WIRE)--When Virionyx, a New Zealand biotechnology company, tested a new anthrax vaccine, company scientists were elated when it worked, but then dumbfounded when one of the negative control agents compared to the vaccine also provided an unexpected level of protection against the bacterial toxin. That finding has led rapidly to a breakthrough that could help protect against a wide range of infectious diseases and possibly fight certain cancers.
